Alfacalcidol in treatment of osteoporosis and prevention of osteoporotic fractures

Authors

DOI:

https://doi.org/10.15674/0030-598720113117-124

Keywords:

osteoporosis, bone mineral density, alfacalcidol

Abstract

Literature data about influence of vitamin D deficiency on the structural-functional state of the bone tissue and systems of the organism are analysed. The article contains results of population studies, that the deficiency of D hormone develops a whole spectrum of pathologic conditions, including osteoporosis. On the basis of the analysis of literature it is concluded that an active metabolite of vitamin D, alfacalcidol, is an effective and safe drug, which is characterized by pleiotropic effect and high pharmacological activity versus vitamin D. Treatment with alfacalcidol reduces the risk of falling down, contributes to improvement of muscle strength and makes it possible to minimize side affects. These features together with prevention of the appearance of new fractures, management of pain syndrome, better motor activity and modulation of the immune system contribute to improvement in the life quality of patients, first of all aged and senile ones. Owing to such a complex effect, the use of alfacalcidol in treatment regimens at a therapeutic dose of 1 mcg/day instead of vitamin D with/without calcium reduces the risk of fractures of their vertebral bodies and the risk of peripheral fractures in this group of patients. Active vitamin D metabolites are able both to decelerate bone mass losses in different types of osteoporosis and even to contribute to improvement of the bone quality. Active metabolites are effective for reducing the risk of falling down, particularly in people with creatinine clearance less than 65 ml/min.

References

  1. Шахт Е. Влияние альфакальцидола на прочность костной ткани и силу скелетных мышц, риск падений и переломов / Е. Шахт, Ф. Ричи, Дж.В. Реджинстер // Проблемы эндокринной патологии. — 2010. — № 2. — С. 112–121.
  2. Торопцова Н.В. Остеопороз: современные подходы в профилактике остеопороза и переломов / Н.В. Торопцова, Л.И. Беневоленская. — Режим доступа к журналу: http://medinfa.ru/article/34/115632/.
  3. Strugnell S.A. The vitamin D receptor structure and transcriptional activation of / S.A. Strugnell, H.F. Deluca // Proceedings the society for experimental biology and medicine. — New York, 1997. — Vol. 215. — P. 223–228.
  4. Шахт Э. Обоснование назначения альфакальцидола (Альфа Д3-Тева) для терапии инволютивного остеопороза у женщин, а также профилактики и терапии глюкокортикоид-индуцированного остеопороза / Э. Шахт // Укр. ревматол. журнал. — 2010. — Т. 41, № 3. — С. 77–84.
  5. Prevalence of vitamin D insufficiency in an adult normal population / M.C. Chapuy, P. Preziosi, M. Maamer et al. // Osteoporos. Int. — 1997. — Vol. 7. — P. 439–443.
  6. Колондаев А.Ф. Значение нарушений метаболизма витамина Д3 и эффективность применения активных метаболитов витамина Д3 у больных остеопорозом старших возрастных групп / А.Ф. Колондаев, С.С. Родионова,И.А.Богданова. — Режим доступа к журналу: http://bone-surgery.ru/view/znachenie_narushenij_metabolizma_vitamina_d3_pri_osteoporoze.
  7. Peak bone mass / R.P. Heaney, S. Abrams, B. Dawson-Hughes et al. // Osteoporos. Int. — 2000. — Vol. 11. — P. 985–1009.
  8. Heaney R.P. Phosphorus nutrition and the treatment of osteoporosis / R.P. Heaney // Mayo Clin. Proc. — 2004. — Vol. 79, № 1. — P. 91–97.
  9. Дамбахер М.А. Остеопороз и активные метаболиты витамина D: мысли, которые приходят в голову / М.А. Дамбахер, Е. Шахт. — Moscow: S.Y.S. Publishing, 1996. — 140 c.
  10. Holik M.F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis / M.F. Holik // Am. J. Clin. Nutr. — 2004. — Vol. 79, № 3. — P. 362–371.
  11. Шварц Г.Я. Витамин D, D-гормон и альфакальцидол: молекулярно-биологические и фармакологические аспекты действия / Г.Я. Шварц // Укр. ревматологічний журнал. — 2009. — Т. 37, № 3. — С. 63–69.
  12. Vitamin D Receptor Expression in human muscle tissue decreases with age / H.A. Bischoff-Ferrari, M. Borchers, F. Gudat et al. // J. Bone Miner. Res. — 2004. — Vol. 19. — P. 265–269.
  13. Costa E.M. 1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells / E.M. Costa, H.M. Blau, D. Feldman // Endocrinology. — 1986. — Vol. 119, № 5. — P. 2214–2220.
  14. de Boland A.R. Nongenomic signal transduction pathway of vitamin D in muscle / A.R. de Boland, R.L. Boland // Cell Signal. — 1994. — Vol. 6. — P. 717–724.
  15. Insulin-like growth factor I and Interleukin-6 contribute synergistically to disability and mortality in older women / A.R. Cappola, Q.L. Xue, L. Ferrucci et al. // J. Clin. Endocrinol. Metab. — 2003. — Vol. 88. — P. 2019–2025.
  16. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol / E. Schacht // Calcif. Tissue Int. — 1999. — Vol. 65. — P. 317–327.
  17. Muscle strength in the elderly: its relation to vitamin D metabolites / H.A. Bischoff, H.B. Stähelin, N. Urscheler et al. // Arch. Phys. Med. Rehabil. — 1999. — Vol. 80. — P. 54–58.
  18. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors / I. Endo, D. Inoue, T. Mitsui et al. // Endocrinology. — 2003. — Vol. 144, № 12. — P. 5138–5144.
  19. Initiation of antigen receptor-dependent differentiation into plasma cells by calmodulin inhibition of E2A / J. Hauser, J. Verma-Gaur, A. Wallenius, T. Grundström // J. Immunol. — 2009. — Vol. 183, № 2. — P. 1179–1187.
  20. Hauser J. Calcium regulation of myogenesis by differential calmodulin inhibition of basic helix-loop-helix transcription factors / J. Hauser, J. Saarikettu, T. Grundstrom // Mol. Biol. Cell. — 2008. — Vol. 19. — P. 2509–2519.
  21. Richy F. Differential effects of D–hormone analogs and native vitamin D on the risk of falls: a comparative meta–analysis / F. Richy, L. Dukas, E. Schacht // Calcif Tissue Int. — 2008. — Vol. 82, № 2. — P. 102–107.
  22. Muscle weakness and falls in older adults: a systematic rewiev and meta-analysis / J.D. Moreland, J.A. Richardson, C.H. Goldsmith, C.M. Clase // J. Am. Geriatr. Soc. — 2004. — Vol. 52. — P. 1121–1129.
  23. Schact E. Reduction of Falls in Elderly. The central role of Alfacalcidol in a multi-dimensional paradigm / E. Schact, F. Richy // The Internet Journal of Epidemiology. — 2009. — Vol. 7, № 1.
  24. Dukas L. In elderly men and women treated for osteoporosisa low creatinine clearance of <65 ml/min is a risk factor for falls and fractures / L. Dukas, E. Schacht, H.B. Stahelin // Osteoporosis Int. — 2005. — Vol. 16, № 12. – P. 1683–1690.
  25. Gallagher J.C. An age related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol / J.C. Gallagher, P.B. Rapuri, L.M. Smith // J. Clin. Endocrinol. Metab. — 2007. — Vol. 92. — P. 51–58.
  26. Przybelski R.J. Is vitamin D important for preserving cognition? A positive correlation of serum 25– hydroxyvitamin D concentration with cognitive function/ R.J. Przybelski, N.C. Binkley // Arch. Biochem. Biophys. — 2007. — Vol. 460, № 2. — Р. 202–205.
  27. Effects of vitamin D2 analogs on calcium metabolism in vitamin D-deficient rats and in MC3T3-E1 osteoblastic cells / F. Sato, Y. Ouchi, Y. Okamoto et al. // Res. Exp. Med. (Berl.). — 1991. — Vol. 191, № 4. — P. 235–242.
  28. Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption / M. Kogawa, D.M. Findlay, P.H. Anderson et al. // Endocrinology. — 2010. — Vol. 151, № 10. — Р. 4613–4625.
  29. Erben R.G. Therapeutic efficacy of 1·,25-dihydroxyvitamin D3 and calcium in osteopenic ovariectomized rats: evidence for a direct anabolic effect of 1·,25-dihydroxyvitamin D3 on bone / R.G. Erben, S. Brown, M. Stangassinger // Endocrinology. — 1998. — Vol. 139. — P. 4319–4328.
  30. Calcitriol corrects bone loss induced by oophorectomy in rats / M.-C. Faugere, S. Okamoto, H.F. DeLuca, H.H. Malluche // Endocrinol. Metab. — 1986. — Vol. 13. — Р. 35–38.
  31. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen / A. Shiraishi, A. Takeda, T. Masaki et al. // J. Bone Miner. Res. — 2000. — Vol. 15. — P. 770–779.
  32. Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats / T. Nishikawa, S. Ogawa, K. Kogita et al. // Bone. — 2000. — Vol. 27. — P. 647–664.
  33. Alfacalcidol restores cancellous bone in ovariectomized rats / M. Li, Y. Li, D.R. Healy et al. // J. Musculoskelet. Neuronal. Interact. — 2003. — Vol. 3. — P. 39–46.
  34. Francis R.M. A comparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures / R.M. Francis // Osteoporosis Int. — 1996. — Vol. 6. — P. 284–290.
  35. Vitamin D and vitamin D analogues for preventing fractures, associated with involutional and postmenopausal osteoporosis / A. Avenell, W.J. Gillespie, L.D. Gillespie, D. O’Connell: [Электронный ресурс]. — Режим доступа: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000227.pub3/abstract;jsessionid=1EE117D96D46BCDCFBEF0C1573B85341.d02t02.
  36. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate / F. Richy, O. Ethgen, O. Bruyere et al. // Osteoporosis Int. — 2004. — Vol. 15. — P. 301–310.
  37. Prevention and treatment of glucocorticoid–induced osteoporosis with active vitamin D3 analogues: a review with meta–analysis of randomized controlled trials including organ transplantation studies / R.N. de Nijs, J.W. Jacobs, A. Algra et al. // Osteoporos Int. — 2004. — Vol. 15, № 8. — P. 589–602.
  38. Prophylactic use of alfacalcidol in corticosteroidinduced osteoporosis / J.Y. Reginster, D. Kuntz, W. Verdickt et al. // Osteoporos. Int. — 1999. — Vol. 9. — P. 75–81.
  39. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis / F. Richy, E. Schacht, O. Bruyere et al. // Calcif. Tissue Int. — 2005. — Vol. 76, № 3. — P. 176–186.
  40. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis update American college of rheumatology Ad Hoc Committee on glucocorticoid-induced // Arthritis Rheumatism. — 2001. — Vol. 44, № 7. — Р. 1496–1503.
  41. Correlation between serum levels of calcium-regulating hormones and soluble markers of immune activation in patients with rheumatoid arthritis / P. Oelzner, S. Franke, A. Muller et al. // Bone. — 1997. — Suppl. 20. — Р. 89.
  42. Mathieu C. The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents / C. Mathieu, L. Adorinet // Trends in Molecular Medicine. — 2002. — Vol. 8. — P. 174–179.
  43. DeLuca H.F. Vitamin D: its role and uses in immunology / H.F. DeLuca, M.T. Cantorna // FASEB J. — 2001. — Vol. 15. — P. 2579–2585.
  44. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level / K. Müller, P.M. Haahr, M. Diamant et al. // Cytokine. — 1992. — Vol. 4, № 6. — P. 506–512.
  45. Scharla S.H. Alfacalcidol versus plain vitamin D in inflammation induced bone loss / S.H. Scharla, E. Schacht, U.G. Lempert // J. Rheumatol. — 2005. — Vol. 76. — P. 26–32.
  46. Schacht E. Osteoporosis in rheumatoid arthritis-significance of alfacalcidol in prevention and therapy / E. Schacht // Z. Rheumatol. — 2000. — Vol. 59, Suppl 1. — Р. 10–20.
  47. Dekel S. The effect of vitamin D and its metabolites on fracture repair in chicks / S. Dekel, R. Salama, S. Edelstein // Clin. Sci. (Lond). — 1983. — Vol. 65, № 4. — P. 429–436.
  48. Effect of 25-OH-vitamin D on fracture healing in elderly rats / A.D. Delgado-Martínez, M.E. Martínez, M.T. Carrascal et al. // J. Orthop. Res. — 1998. — Vol. 16, № 6. — P. 650–653.
  49. Effect of ED-71 on modeling of bone in distraction osteogenesis / K. Yamane, T. Okano, H. Kishimoto, H. Hagino // Bone. — 1999. — Vol. 24, № 3. — P. 187–193.
  50. 1Alpha,25-dihydroxy-2beta(3-hydroxypropoxy)vitamin D3 (ED-71) suppressed callus remodeling but did not interfere with fracture healing in rat femora / Y. Cao, S. Mori , T. Mashiba et al. // Bone. — 2007. — Vol. 40, № 1. — P. 132–139.
  51. 25-hydroxyvitamin D, parathyroid hormone, and functional recovery after hip fracture in elderly patients / M. Di Monaco, F. Vallero, R. Di Monaco et al. // J. Bone Miner. Metab. — 2006. — Vol. 24, № 1. — P. 42–47.
  52. Использование миокальцика и альфакальцидола в комплексном лечении переломов проксимального отделабедренной кости у лиц пожилого возраста / Э.И. Солод, С.С. Родионова, А.Ф. Лазарев и др. // Остеопороз и остеопения. — 1999. — № 1. — C. 37–39.
  53. Миронов С.П. Тотальное эндопротезирование тазобедренного сустава бесцементными имплантатами ЭСИ (Пособие для врачей) / С.П. Миронов, В.И. Нуждин, O.A. Кудинов [Электрон. ресурс]. — Режим доступа: http://endosys.ru/metod.
  54. Родионова С.С. Принципы лечения переломов и эндопротезирования суставов на фоне остеопороза / С.С. Родионова // Руководство по остеопорозу / Л.И. Беневоленская. — М.: БИНОМ, 2003. — C. 304–319.
  55. Curative effect of combined treatment with alendronate and 1-аlfahydroxyvitamin D3 on bone loss by ovariectomy in aged rats / M. Ito, Y. Azuma, H. Takagi et al. // Jpn J. Pharmacol. — 2002. — Vol. 89. — P. 255–266.
  56. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal women or male osteoporosis (AAC–Trial) / J.D. Ringe, P. Farahmand, E. Schacht, A. Rozehnal // Rheumatol Int. — 2007. –Vol. 27, № 5. — P. 425–434.
  57. Alendronate of Alfacflcidol in glucocorticoid–induced osteoporosis / R.N. De Nijs, J.W. Jacobs, W.F. Lems et al. // N. Engl. J. Med. — 2006. — Vol. 355, № 7. — P. 675–684.
  58. Comparative studies on effect of risedronate and alfacflcidol against glucocorticoid–induced osteoporosis in rheumatoid arthritic patients / S. Yamada, H. Takagi, H. Tsuchiya et al. // Yakugaku Zasshi. — 2007. — Vol. 127, № 9. — P. 1491–1496.
  59. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation–induced osteoporosis / J.D. Ringe, H. Faber, P. Fahramand, E. Schacht // J. Rheumatol. Suppl. — 2005. — Vol. 76. — P. 33–40.
  60. Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years randomized, multiarm, controlled trial / K. Ones, E. Schacht, L. Dukes, N. Caglar // The Internet Journal of Epidemiology. — 2007. — Vol. 4, № 1.
  61. Superiority of Alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis / R. Nuti, G. Bianchi, M.L. Brandi et al. // Rheumatol. Int. — 2006. — Vol. 26. — P. 445–453.
  62. Orimo H. Clinical Application of 1α(OH)D3 in Japan / H. Orimo // Akt. Rheumatol. — 1994. — Suppl. 19. — Р. 27–30.

Downloads

How to Cite

Korzh, M., Dedukh, N., & Pobel, Y. (2011). Alfacalcidol in treatment of osteoporosis and prevention of osteoporotic fractures. ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS, (3), 117–124. https://doi.org/10.15674/0030-598720113117-124

Issue

No. 3 (2011)

Section

DIGESTS AND REVIEWS

License

Copyright (c) 2014 Mykola Korzh, Ninel Diedukh, Yevgeny Pobel

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.

Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.

The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).